Form 8-K - Current report:
SEC Accession No. 0001493152-24-041623
Filing Date
2024-10-18
Accepted
2024-10-18 17:25:48
Documents
15
Period of Report
2024-10-17
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46967
2 ex99-1.htm EX-99.1 9875
  Complete submission text file 0001493152-24-041623.txt   287572

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cldi-20241017.xsd EX-101.SCH 3813
4 XBRL DEFINITION FILE cldi-20241017_def.xml EX-101.DEF 30090
5 XBRL LABEL FILE cldi-20241017_lab.xml EX-101.LAB 36817
6 XBRL PRESENTATION FILE cldi-20241017_pre.xml EX-101.PRE 27113
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5966
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 241381522
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)